TY - T1的预后的重要性脑瘤特定健康相关的生活质量缺陷和疲劳在新诊断的胶质母细胞瘤(P1.162) JF -神经学乔-神经学六世- 88 - 16补充SP - P1.162盟凯瑟琳·彼得斯AU -玛丽卢Affronti盟盟Eric Lipp Janet Minchew AU -弗朗西斯McSherry盟詹姆斯·赫恩登二首页世盟——伊丽莎白·米勒盟迪娜事务非盟- Annick德斯贾丁斯盟Gordana Vlahovic AU -亨利·弗里德曼Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P1.162.abstract N2 -目的:从我们先前发表的报告,我们已经表明,与健康相关的生活质量(HRQoL)和疲劳措施生存的独立预后因素复发胶质母细胞瘤(GBM)患者。因此,我们试图评价HRQoL和疲劳的影响在最近确诊GBM患者生存。背景:尽管“绿带运动”的治疗持续进步,仍有相当大的发病率和死亡率与这种疾病有关。在疾病过程中,GBM患者经常体验HRQoL疲劳和挑战。设计/方法:收集的数据作为进步的一部分注册11/21/2011和10/10/2013之间查询。数据来自patient-reported结果问卷包括功能评估癌症Therapy-Brain (FACT-Br)和慢性疾病的功能评估Therapy-Fatigue (FACIT-F)。FACT-Br包含一般HRQoL物理措施、社会、情感、和功能性健康和脑癌次生氧化皮,捕捉特定于原发性脑瘤患者的担忧。似然比(LR)测试是使用Cox模型来评估HRQoL的贡献和疲劳之外,传统的整体生存预后变量。结果:322名受试者完成FACIT-F确认完成FACT-Br与281年和262年。平均年龄是59岁(SD = 13)年。KPS 90≥36.7%, KPS = 80为34.5%,KPS≤70年为21.4%。 In univariate analyses, all measures of HRQoL and fatigue were significant predictors of survival, but the majority of measures did not add prognostic value in multivariate analyses including age, KPS, and extent of resection. Interestingly, with a LR p-value=0.007, the FACT-Br Brain Cancer Subscale added significant prognostic value beyond KPS, age, and extent of resection (HR=0.983 (95% CI, 0.973–0.993); p<0.001).Conclusions: Recognition of primary brain tumor specific problems in HRQoL can aid in the prognostication for patients with newly-diagnosed GBM beyond traditional prognostic factors. Identification and treatment of these primary brain tumor specific HRQoL challenges could provide a means to impact prognosis.Disclosure: Dr. Peters has received research support from Agios, AMGEN, BioMimetix, Eisai, Merck, and VBL. Dr. Affronti has received research support from Eisai Inc. and Merck. Dr. Lipp has nothing to disclose. Dr. Minchew has nothing to disclose. Dr. McSherry has nothing to disclose. Dr. Herndon II has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Randazzo has nothing to disclose. Dr. DesJardins has received personal compensation for activities with Genentech, Cavion, Novartis, EMD Serono, and PTC Therapeutics. Dr. DesJardins holds stock and/or stock options with IST GmbH. Dr. Vlahovic has received personal compensation for activities with Genentech, Merck and BMS for participating on the speaker bureau or advisory board. Dr. Friedman has received personal compensation for activities with Genentech as an advisory board member or speaker. ER -